ReviewExperimental biology and medicine (Maywood, N.J.)2016
Targeting and therapeutic peptides in nanomedicine for atherosclerosis.
Review in Experimental biology and medicine (Maywood, N.J.), 2016. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Cited by 20 papers.
What it found
Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.
The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.
The trial behind it
Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.
Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.
Who cites it
20 citing papers in PubMed.
- Stem cell-derived exosome delivery systems for treating atherosclerosis: The new frontier of stem cell therapy.Materials today. Bio · 2025Review
- Oleaceae plants: a source of metabolites with atheroprotective potential.Frontiers in pharmacology · 2025Review
- Photodynamic Therapy for Atherosclerosis.International journal of molecular sciences · 2024Review
- Atherosclerosis treatment with nanoagent: potential targets, stimulus signals and drug delivery mechanisms.Frontiers in bioengineering and biotechnology · 2023Review
- Surface-modified nanotherapeutics targeting atherosclerosis.Biomaterials science · 2022Review
- Therapeutic Response of miR-145 Micelles on Patient-Derived Vascular Smooth Muscle Cells.Frontiers in digital health · 2022Article
- Theranostic nanoplatform to target macrophages enables the inhibition of atherosclerosis progression and fluorescence imaging of plaque in ApoE(-/-) mice.Journal of nanobiotechnology · 2021Article
- Exosomes in Atherosclerosis, a Double-Edged Sword: Their Role in Disease Pathogenesis and Their Potential as Novel Therapeutics.The AAPS journal · 2021Review
- Transdermal Delivery of Kidney-Targeting Nanoparticles Using Dissolvable Microneedles.Cellular and molecular bioengineering · 2020Article
- Peptide-based targeting of immunosuppressive cells in cancer.Bioactive materials · 2020Review
- The CD44-HA axis and inflammation in atherosclerosis: A temporal perspective.Matrix biology : journal of the International Society for Matrix Biology · 2019Review
- Shape Effects of Peptide Amphiphile Micelles for Targeting Monocytes.Molecules (Basel, Switzerland) · 2018Article
- Theranostic Nanoparticles for Tracking and Monitoring Disease State.SLAS technology · 2018Review
- Protein Mimetic and Anticancer Properties of Monocyte-Targeting Peptide Amphiphile Micelles.ACS biomaterials science & engineering · 2017Article
- Synthesis of Monocyte-targeting Peptide Amphiphile Micelles for Imaging of Atherosclerosis.Journal of visualized experiments : JoVE · 2017Article
- Peptide and antibody ligands for renal targeting: nanomedicine strategies for kidney disease.Biomaterials science · 2017Article
- Targeting cell adhesion molecules with nanoparticles using in vivo and flow-based in vitro models of atherosclerosis.Experimental biology and medicine (Maywood, N.J.) · 2017Review
- Self-assembling peptide-based building blocks in medical applications.Advanced drug delivery reviews · 2017Review
- Gadolinium-Functionalized Peptide Amphiphile Micelles for Multimodal Imaging of Atherosclerotic Lesions.ACS omega · 2016Article
- Cytokines: roles in atherosclerosis disease progression and potential therapeutic targets.Future medicinal chemistry · 2016Review
Corrections and comments
PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.
Authors and funding
1 author.
Funding
Abstract
Peptides in atherosclerosis nanomedicine provide structural, targeting, and therapeutic functionality and can assist in overcoming delivery barriers of traditional pharmaceuticals. Moreover, their inherent biocompatibility and biodegradability make them especially attractive as materials intended for use in vivo In this review, an overview of nanoparticle-associated targeting and therapeutic peptides for atherosclerosis is provided, including peptides designed for cellular targets such as endothelial cells, monocytes, and macrophages as well as for plaque components such as collagen and fibrin. An emphasis is placed on recent advances in multimodal strategies and a discussion on current challenges and barriers for clinical applicability is presented.
Indexed as
Identifiers
What OpenQuestion holds
Registered trials
Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.